<DOC>
	<DOCNO>NCT01213316</DOCNO>
	<brief_summary>This observational , non-comparative , multicenter , open-label study . Participants treat Raltegravir accord standard clinical practice , monitor total period 96 week . In extension study ( Amendment 1 ) , new cohort age participant ( ≥ 50 year ) recruit monitored total period 48 week . Participants stop take Raltegravir end 96-week period 48-week period , respectively , follow 3 month discontinue drug . The primary objective determine proportion participant human immunodeficiency virus ( HIV ) -1 viral load &lt; 50 copies/mL 48 week treatment Raltegravir .</brief_summary>
	<brief_title>A Study Assess Efficacy Raltegravir ( Isentress® ) , Administered Combination With Other Antiretroviral Drugs Treatment Adults Older Adults Infected With Human Immunodeficiency Virus 1 ( HIV-1 ) ( MK-0518-145 ) ( Wirksamkeit Von Isentress® Unter Praxisbedingungen )</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>Inclusion Criteria The prospective participant must meet , least , criterion eligible study participation . The participant : Is minimum age 18 year ( adult ) 50 year ( age participant ) ; Is male female ; Has confirm infection HIV1 ( positive HIV test accord appropriate standard practice ) ; Has commence antiretroviral treatment Raltegravir accord recommendation make Summary Product Characteristics time enrollment study , maximum 6 month prior enrollment study ; Has cluster differentiation ( CD4 ) cell ( specialized white blood cell ) count upon enrollment study . Exclusion criterion If prospective participant meet criteria ( among others determine study staff ) NOT eligible study participation . The participant : For Raltegravir , ingredient , contraindicate ; Has intolerance Raltegravir , ingredient ; If female , pregnant , breastfeeding , plan pregnancy egg donation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>HIV</keyword>
	<keyword>antiretroviral</keyword>
	<keyword>human immunodeficiency virus</keyword>
	<keyword>Raltegravir</keyword>
	<keyword>Adults HIV-1 infection</keyword>
</DOC>